IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026
Key Highlights
- ➤IMUNON schedules Q3 2026 financial results and business update call for November 12
- ➤IMNN-001 Phase 3 development advances in newly diagnosed advanced ovarian cancer
- ➤IMUNON completes dosing in first-in-human IMNN-101 COVID-19 booster vaccine study
LAWRENCEVILLE, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a conference call at 11:00 a.m. EST on Thursday, November 12, 2026 to discuss financial results for the quarter ended September 30, 2026 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy, including progress in advancing Phase 3 clinical development of IMNN-001 in newly diagnosed advanced ovarian cancer.
To participate in the call, please dial (800) 715-9871 (U.S. and Canada/Toll Free) or (646) 307-1963 (U.S./Toll) and ask for the IMUNON Third Quarter 2026 Financial Results Call (Conference ID 4174261). A live webcast of the call will also be available here.
Get started
Create a free account to read the full story.